Skip to main content
BMS' marketing application for lung cancer combo accepted by FDA

The FDA has accepted the marketing application filed by Bristol-Myers Squibb for its lung cancer combination of Opdivo, or nivolumab, plus Yervoy, or ipilimumab, as a first-line treatment for patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK mutations. An action date of May 15 was set by the agency.

Full Story: